Australian Influenza Surveillance Report
Communicable Disease Epidemiology and Surveillance Section (CDESS)
Report no. 03, 2023
Reporting fortnight: Monday 1 May 2023 to Sunday 14 May 2023.

Reporting weeks: 18 and 19, of 2023.

The Department of Health and Aged Care acknowledges the providers of the many sources of data used in this report and greatly appreciates their contribution.

Key Messages

It is important to note that due to the COVID-19 epidemic in Australia, data reported from the various influenza surveillance systems may not represent an accurate reflection of influenza activity. Results should be interpreted with caution, especially where comparisons are made to previous influenza seasons. Interpretation of influenza data from April 2020 onwards should take into account, but are not limited to, the impact of social distancing measures, likely changes in health seeking behaviour of the community including access to alternative streams of acute respiratory infection specific health services, and focussed testing for COVID-19 response activities. For information on COVID-19 incidence, severity, and distribution in Australia, please refer to the COVID-19 epidemiology reports.

Note: This fortnightly report does not contain data from the HealthDirect surveillance system due to temporary data transmission issues. Data will be included in future reports.

Activity:

- Influenza-like-illness (ILI) activity in the community has increased this fortnight.
- Across all jurisdictions, the number of notifications of laboratory-confirmed influenza has increased this fortnight.
- In the year-to-date (1 January to 14 May 2023), there have been 40,318 notifications reported to the National Notifiable Diseases Surveillance System (NNDSS) in Australia, of which 8,173 notifications had a diagnosis date this fortnight.

Severity:

- There is currently not enough information to comprehensively assess the potential severity of the 2023 influenza season at this time.
- In the year-to-date, of the 40,318 notifications of laboratory-confirmed influenza, 44 influenza-associated deaths have been notified to the NNDSS.
- Since seasonal surveillance commenced in April 2023, there have been 314 sentinel hospital admissions, of which 22 (7%) were admitted directly to ICU.

Impact:

- Although the number of laboratory-confirmed influenza notifications in the year to date is currently higher than the 5-year average*, community ILLI activity remains within historical ranges, and it is likely there is low impact on society due to influenza in 2023 to date.

At-risk populations:

- In the year-to-date, notification rates have been highest in people aged 05–09 years, followed by those aged 0–04 years, and 10–14 years.

Virology:

- In the year-to-date, 77% of notifications of laboratory-confirmed influenza reported to the NNDSS were influenza A, of which 95% were influenza A(unsubtyped); 4% were influenza A(H1N1); and 1% were influenza A(H3N2). Influenza B accounted for
22.6% of notifications; influenza A&B accounted for 0.04% of notifications; and 1% of influenza notifications were untyped.

<table>
<thead>
<tr>
<th>Vaccine match and effectiveness:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Of the 818 samples referred to the WHOCC in the year-to-date, 95.9% of influenza A(H1N1) isolates, 75.0% of influenza A(H3N2) isolates, and 99.4% of influenza B/Victoria isolates characterised were antigenically similar to the corresponding vaccine components.</td>
</tr>
<tr>
<td>It is too early to assess vaccine match and effectiveness for this season.</td>
</tr>
</tbody>
</table>

*The years 2020 and 2021 have been excluded when comparing the current season to historical periods (including the 5-year average) when influenza virus has circulated without public health restrictions. Please refer to Data considerations for interpretation of the five-year average.*

1. Introduction

Each year, the influenza virus changes and different strains can circulate in the population. Particular subtypes of influenza can affect different groups of the population more than others. Depending on the susceptibility of the population, the subtypes that are circulating and the changes to the virus itself, the influenza season can be very different year to year. Our surveillance systems help us to understand influenza activity, severity of the infection in individuals and impact of the illness on society in Australia. We are also able to monitor which influenza viruses are circulating, which populations might be more affected, the effectiveness of the vaccine, and any resistance to antiviral drugs that has developed.

1.1. National Influenza Surveillance System

This report presents an overview of influenza activity based on a number of complimentary systems. No one single system, including notification data, provides the full picture on influenza, because influenza is a common disease and its presenting symptoms are non-specific. The epidemiology of influenza is informed by a number of different systems based in the community, laboratories, primary care and hospitals, as well as notifiable diseases data, which includes officially reported deaths. The information in this report is reliant on the surveillance sources available to the Department of Health and Aged Care at the time of production.

- The National Notifiable Diseases Surveillance System (NNDSS) coordinates the national surveillance of more than 60 communicable diseases or disease groups. Notifications of laboratory-confirmed influenza are made to state or territory health authorities and supplied daily to the Australian Government Department of Health and Aged Care via the NNDSS for collation, analysis, and to assist in the coordination of public health responses.

- Healthdirect provides free health triage advice and information services by telephone and online, and can assist in identifying symptoms including those that may be classified as an ILI syndrome. Community level ILI syndromic trends are monitored using Healthdirect data.

- FluTracking is an online syndromic surveillance system which monitors ILI in the community.
• The Australian Sentinel Practices Research Network (ASPREN) is a year-round sentinel general practice (GP) surveillance system in which general and nurse practitioners report de-identified information on the number of ILI patient presentations seen in participating practices each week. It should be noted that in addition to the overarching impacts of COVID-19 on influenza surveillance systems, interpretation of ASPREN’s data from 2020 onwards should consider the following COVID-19 impacts:
  – Changes in the health seeking behaviour at ASPREN sentinel sites due to the availability of telehealth and respiratory clinics may result in fewer presentations to General Practice (GP); and
  – Changes to GPs swabbing at ASPREN sentinel sites, due to the availability of telehealth and respiratory clinics, may result in a lower number of swabs being undertaken by ASPREN reporters.

• The Influenza Complications Alert Network (FluCAN) conducts surveillance of severe influenza at sentinel hospitals across the country during the influenza season. The Paediatric Active Enhanced Disease Surveillance (PAEDS) network also contributes data on influenza via FluCAN.

• The World Health Organization Collaborating Centre (WHOCC) for Reference and Research on Influenza analyses influenza viruses currently circulating in the human population in Australia and other countries, to inform which strains should be included in annual seasonal influenza vaccines for the Northern and Southern Hemispheres.

• Sentinel laboratory surveillance systems provide fortnightly reporting of influenza testing. This includes the number of tests undertaken, the number of positive results, and the detected viruses. Sentinel laboratory site testing data are influenced by jurisdictional and laboratory testing practices, and should be interpreted with caution. Please note that tests conducted at sentinel laboratory sites may include samples taken from people in home or hotel quarantine for COVID-19, and may not reflect respiratory viruses circulating in the community alone.

1.2. Data considerations
• NNDSS laboratory-confirmed influenza surveillance case definition
  – From 1 January 2022, the NNDSS surveillance case definition for laboratory-confirmed influenza was updated to remove Point 5: ‘Single high titre by complement fixation test (CFT) or haemagglutination inhibition (HAI) to influenza virus’ from the list of laboratory definitive evidence.
  – This change has minimal impact on the interpretation of influenza notification trends, with the change ensuring consistency with the influenza laboratory case definition. For further information, please refer to the NNDSS laboratory-confirmed influenza case definition Technical Supplement.

• Data in this summary is reported by International Organization for Standardization (ISO) 8601 weeks, with the week ending on Sunday. Throughout the summary, where the year-to-date is presented, this includes data from 1 January to 14 May. NNDSS data are analysed and reported based on diagnosis date, which is the true
onset date of a case if known, otherwise it is the earliest of the specimen date, the notification date, or the notification received date. NNDSS data were extracted on Thursday 18 May 2023.

- In interpreting these data, it is important to note that changes in notifications over time may not solely reflect changes in disease prevalence or incidence. Depending on the disease, the number of notifications may be influenced by changes in testing policies; changes in case definitions; changes in testing practices and screening programs; the use of less invasive and more sensitive diagnostic tests; and periodic awareness campaigns.

- In particular, analyses including data from 2020 and 2021 should be interpreted with caution. Influenza activity in 2020 and 2021 was unusual due to the suppression of influenza virus circulation because of COVID-19 mitigation measures. Data from these years may reduce five-year averages and affect analyses of usual seasonal trends. Therefore the years 2020 and 2021 are excluded in this report when comparing the current season to historical periods when influenza virus has circulated without public health restrictions. Where referenced, the 5-year average in this report refers to the average of data from the years 2016, 2017, 2018, 2019, and 2022.

- Due to the dynamic nature of the NNDSS and other surveillance systems, data in this report are subject to retrospective revision and may vary from data reported in other national reports and reports by states and territories. Detailed notes on interpreting the data presented in this report are available at the Department of Health and Aged Care’s Australian Influenza Surveillance Report website. While every care has been taken in preparing this report, the Commonwealth does not accept liability for any injury or loss or damage arising from the use of, or reliance upon, the content of the report. Delays in the reporting of data may cause data to change retrospectively. For further details about information contained in this report please contact the Influenza Surveillance Team (flu@health.gov.au).
2. Analysis

2.1. Activity

Activity measures the capacity of the circulating influenza viruses to spread person to person and may be measured indirectly through systems that monitor influenza-like illness and more directly through systems that monitor laboratory-confirmed influenza.

2.1.1. Influenza-like illness (ILI)

FluTracking

- This fortnight (1 May to 14 May 2023), the proportion of FluTracking participants reporting ILI (fever and cough) was 1.2%, an increase compared to 0.98% in the previous fortnight.
- Following a decrease in mid-April, the proportion of FluTracking participants reporting ILI has begun to increase again (Figure 1).

Sentinel General Practitioners (ASPREN)

- This fortnight (1 May to 14 May 2023), an average of 3.4 per 1,000 consultations due to ILI were reported by sentinel ASPREN GPs, an increase compared to 2.4 per 1,000 consultations in the previous fortnight.
- In the year-to-date, sentinel ASPREN GPs have reported between 0.5 and 3.5 consultations due to ILI per 1,000 consultations per week. The highest ILI rate to date this year was observed in week 19 (3.5 per 1,000 consultations), following an increase in the ILI rate over the past fortnight (Figure 2).
- In the year-to-date, 240 people presenting to a sentinel ASPREN GP with ILI were tested for respiratory viruses, of which 30 (12.5%) samples were positive for influenza.
- In the year-to-date, of those presenting to sentinel ASPREN GPs with ILI who were tested for respiratory viruses, 56.7% (136/240) tested positive for a respiratory virus. Among those positive for a respiratory virus, the most common virus reported was rhinovirus (34.6%, 47/136). Other viruses detected included SARS-CoV-2 (22.8%), influenza (22.1%), respiratory syncytial virus (8.8%), parainfluenza virus type-2 (2.9%), and adenovirus (2.9%).

Sentinel laboratories

- This fortnight (1 May to 14 May 2023) the most commonly detected respiratory viruses* by sentinel laboratory site and week were as follows:
  - New South Wales: COVID 19 (both weeks);
  - South Australia: Rhinovirus (both weeks);
  - Tasmania: COVID-19 (both weeks);
  - Victoria: Picornavirus (both weeks);
  - Western Australia: Influenza A (both weeks).

*Excludes SARS-CoV-2 for laboratory data reported by Tasmania and WA.
Figure 1: Proportion of fever and cough among FluTracking participants, Australia, 2016 to 2023, by year and week of report*^
Figure 2: Unweighted rate of ILI reported from ASPREN sentinel GP surveillance systems, Australia, 1 January 2016 to 14 May 2023, by year and week**

Source: ASPREN

*All data are preliminary and subject to change as updates are received, with most recent weeks considered particularly subject to revisions. The years 2020 and 2021 are excluded when comparing the current season to historical periods when influenza virus has circulated without public health restrictions. Please refer to Data considerations for interpretation of the five-year average.

**Please refer to surveillance system description for notes on impact of COVID-19 on ASPREN data.

2.1.2. Laboratory-confirmed influenza

National notification data (NNDSS):

- There were 8,173 laboratory-confirmed influenza notifications with a diagnosis date this fortnight (1 May to 14 May 2023), an increase compared to 6,159 notifications in the previous fortnight (Figure 3).

- In the year-to-date, there have been 40,318 notifications of laboratory-confirmed influenza to the NNDSS. This is a national notification rate of 155 cases per 100,000 population.

ASPREN

- In the year-to-date, there have been 30 (12.5%) influenza detections among the 240 ILI cases presenting to sentinel GPs who were tested for respiratory viruses.

Sentinel laboratories

- This fortnight (1 May to 14 May 2023), of the 20,001 samples tested across sentinel laboratories, 3.8% (n=770) have been positive for influenza, a decrease compared to 4.3% in the previous fortnight (Figure 4).
• Of the 144,372 samples tested across sentinel laboratories in the year-to-date, 2.7% (n=3,936) have been positive for influenza.

**Figure 3:** Notifications of laboratory-confirmed influenza, Australia, 1 January 2016 to 14 May 2023, by year and week of diagnosis*

*Source: NNDSS

*NNDSS notification data provided for the current and most recent weeks may be incomplete. All data are preliminary and subject to change as updates are received, with most recent weeks considered particularly subject to revisions. The years 2020 and 2021 are excluded when comparing the current season to historical periods when influenza virus has circulated without public health restrictions. Please refer to Data considerations for interpretation of the five-year average.
**Figure 4:** Proportion of sentinel laboratory tests positive for influenza and total number of specimens tested, 1 January to 14 May 2023, by subtype, year and week*

![Graph showing proportion of sentinel laboratory tests positive for influenza and total number of specimens tested by subtype, year, and week.](image)

*Total number of tests include all specimens that were tested for influenza, including multiplex panels used to test for SARS-CoV-2. Testing methodologies vary across jurisdictions and laboratories. All data are preliminary and subject to change as updates are received, with most recent weeks considered particularly subject to revisions.

### 2.1.3. Geographical distribution of influenza activity

**National notification data (NNDSS):**

- In the year to date, influenza notification rates have been highest in the Northern Territory (513 notifications per 100,000 population) followed by Queensland (228 notifications per 100,000 population) (Table 1).
- This fortnight (1 May to 14 May 2023), influenza activity has increased across all jurisdictions (Figure 5).

**Table 1:** Laboratory-confirmed influenza notifications to the NNDSS and notification rate per 100,000 population by jurisdiction, 1 January to 14 May 2023*

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>ACT</th>
<th>NSW</th>
<th>NT</th>
<th>QLD</th>
<th>SA</th>
<th>TAS</th>
<th>VIC</th>
<th>WA</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of notifications</td>
<td>290</td>
<td>12,736</td>
<td>1,285</td>
<td>12,156</td>
<td>2,731</td>
<td>290</td>
<td>7,528</td>
<td>3,302</td>
<td>40,318</td>
</tr>
<tr>
<td>Notification rate per 100,000 population</td>
<td>64</td>
<td>156</td>
<td>513</td>
<td>228</td>
<td>150</td>
<td>51</td>
<td>114</td>
<td>119</td>
<td>155</td>
</tr>
</tbody>
</table>
**Figure 5:** Notifications of laboratory-confirmed influenza*, 1 January to 14 May 2023, by state or territory and week of diagnosis

*Source: NNDSS

*NNDSS notification data provided for the current and most recent weeks may be incomplete. All data are preliminary and subject to change as updates are received, with most recent weeks considered particularly subject to revisions.

For further information regarding influenza activity at the jurisdictional level, please refer to the following State and Territory health surveillance reports:

- **ACT:** [ACT Influenza Report](#)
- **NSW:** [Respiratory surveillance reports](#)
- **QLD:** [Statewide Weekly Influenza Surveillance Report](#)
- **SA:** [Weekly Epidemiological Summary](#) (Influenza section)
- **TAS:** [fluTAS Reports](#)
- **VIC:** [Influenza Surveillance Reports](#)
- **WA:** [Virus WAtch](#)
2.2. Severity

Severity is a measure of adverse outcomes or complications as a result of ILI such as hospital referrals, admissions, need for intensive care, and deaths. Measuring and understanding the severity of circulating influenza is difficult to establish at the beginning, or during a low, influenza season. The proportion of confirmed influenza cases with serious outcomes might be skewed initially because there are only a small number of people notified. This means that the measure of severity will vary substantially fortnight to fortnight until numbers are sufficiently high and there is enough data for measurements to stabilise. An assessment of severity can be provided once the signals become clearer.

**FluCAN:**

- This fortnight (1 May to 14 May 2023), there have been 40 hospitalisations due to influenza across FluCAN sentinel hospital sites, of which 4 cases were admitted directly to ICU (10%) (Figure 6).
- Since seasonal surveillance commenced in April 2023, there have been 314 sentinel hospital admissions due to confirmed influenza, of which 22 (7%) were admitted directly to ICU.

**National notification data (NNDSS):**

- In the year-to-date, of the 40,318 notifications of laboratory-confirmed influenza, there have been 44 influenza-associated deaths notified to the NNDSS*.
- 77% of influenza-associated deaths were attributed to influenza A(unsubtyped), 14% to influenza B, 5% to influenza A(H1N1), and 5% to influenza A(H3N2).
- The median age of deaths notified was 74.5 years.

*The number of influenza-associated deaths reported to the NNDSS does not represent the true mortality associated with this disease. The number of deaths is reliant on the follow up of cases to determine the outcome of their infection. The follow up of cases is not a requirement of notification and are only inclusive of laboratory-confirmed cases of influenza. Due to retrospective revision, the variation across jurisdictions in methodology, representativeness, and timeliness of death data, and reporting of an outcome of infection not being a requirement of notification, year on year comparisons of deaths in notified cases of influenza may not be reliable.
**Figure 6:** Number of influenza hospitalisations at sentinel hospitals, from April to October, 2016 to 2023 by year and week of diagnosis*

![Graph showing number of hospitalisations]

*All data are preliminary and subject to change as updates are received, with most recent weeks considered particularly subject to revisions. The years 2020 and 2021 are excluded when comparing the current season to historical periods when influenza virus has circulated without public health restrictions. Please refer to Data considerations for interpretation of the five-year average.

### 2.3. Impact

Impact measures how influenza affects society, including stress on health-care resources and societal and economic consequences.

**FluTracking**

- This fortnight (1 May to 14 May 2023), the proportion of FluTracking participants reporting ILI and taking time off regular work duties while unwell was 0.88%, an increase compared to 0.67% in the previous fortnight.
- Following a decrease in mid-April, the proportion of FluTracking participants reporting ILI and taking time off regular duties while unwell has begun to increase again.

**FluCAN:**

- Since seasonal surveillance commenced in April 2023, there have been 314 sentinel hospital admissions due to confirmed influenza, of which 22 (7%) were admitted directly to ICU.
2.4. At-risk population

At-risk populations are people who may be more susceptible to infection with the influenza virus and/or who may be more likely to experience severe outcomes from their infection.

National notification data (NNDSS):

- In the year-to-date, notification rates have been highest in people aged 05–09 years (447 notifications per 100,000 population), followed by those aged 0–04 years (325 notifications per 100,000 population), and those aged 10–14 years (230 notifications per 100,000 population).

- In the year-to-date, influenza A accounted for the highest rate of notifications across all age groups (Figure 7).

FluCAN:

- Since seasonal surveillance commenced in April 2023, 77% of people admitted with confirmed influenza across sentinel hospital sites were children aged younger than 16 years*, 12% were adults aged 16 to 64 years, and 11% were adults aged 65 years or older.

- Of children aged younger than 16 years admitted with confirmed influenza to date, 6% were admitted directly to ICU, compared to 19% of adults aged 16 to 64 years, and 3% of adults aged 65 years or older.

*Hospital admissions in children under 16 years of age are over-represented in the FluCAN data in order to provide increased information on this at-risk population. The age distribution of hospital admissions in the FluCAN sentinel surveillance system may not reflect the age distribution of all influenza admissions nationally.

Figure 7: Rate of notifications of laboratory-confirmed influenza, Australia, 1 January to 14 May 2023, by age group and subtype*

Source: NNDSS

*All data are preliminary and subject to change as updates are received.
2.5. Virology

National notification data (NNDSS):

- Of the 8,173 notifications of laboratory-confirmed influenza reported to the NNDSS this fortnight (1 May to 14 May 2023), 74% (n=6,072) were influenza A (unsubtyped); 23% (n=1,879) were influenza B; 2% (n=163) were influenza A(H1N1); and 0.1% were influenza A(H3N2). One percent (n=50) were untyped.
- In the year-to-date, 77% of notifications of laboratory-confirmed influenza reported to the NNDSS were influenza A (30,946/40,318), of which 95% were influenza A (unsubtyped); 4% were influenza A(H1N1); and 1% were influenza A(H3N2). Influenza B accounted for 22.6% of notifications (9,127/40,318), and influenza A&B accounted for 0.04% of notifications (15/40,318). One percent of notifications were untyped (230/40,318) (Figure 8).
- In the year to date, influenza A has accounted for the majority of influenza notifications in most jurisdictions. In the Northern Territory however, influenza B still accounts for the highest proportion of notifications (Figure 9).

ASPREN

- In the year-to-date, there have been 30 influenza-positive samples detected through ASPREN GPs. Influenza A accounted for 63% (19/30) of these, of which 68% (13/19) were A(H1N1); 16% (3/19) were A(H3N2); and 16% (3/19) were A (unsubtyped). Influenza B accounted for 37% (11/30), of which 82% (9/11) were influenza B (unsubtyped), and 18% (2/11) were influenza B/Victoria.

FluCAN

- Since seasonal surveillance commenced in April 2023, of the 314 hospital admissions across sentinel hospitals, 74% (232/314) were due to influenza A, and 26% (82/314) were due to influenza B. Of the hospital admissions due to influenza A, 78.4% (182/232) were A (unsubtyped), 19.4% were A(H1N1), and 2.2% were A(H3N2).
- Of the 22 patients admitted to ICU, 77.3% (17/22) were due to influenza A, and 22.7% (5/22) were due to influenza B. Of the ICU admissions due to influenza A, 14 were A (unsubtyped), 2 were A(H1N1), and 1 was A(H3N2).

Sentinel laboratories

- Of the 3,936 influenza positive samples in the year-to-date, 69% (n=2,716) were influenza A, of which 36.8% (n=1,000) were influenza A (unsubtyped); 15% (n=408) were A(H1N1); and 3.1% (n=84) were A(H3N2). Influenza B accounted for 31% of positive samples (n=1,220).

WHOCC

- From 1 January to 14 May 2023, the WHOCC characterised 818 influenza viruses. Of these, 44.7% (n=366) were influenza A(H1N1), 15.2% (n=124) were influenza A(H3N2), and 40.1% (n=328) were influenza B/Victoria (Table 2).
- In the year to date, none of the influenza A(H1N1), A(H3N2), or influenza B/Victoria samples tested for neuraminidase inhibitor resistance have demonstrated reduced inhibition to Oseltamivir or Zanamivir.
Figure 8: Percent of notifications of laboratory-confirmed influenza, Australia, 1 January to 14 May 2023, by subtype and week of diagnosis*

Source: NNDSS

*NNDSS notification data provided for the current and most recent weeks may be incomplete. All data are preliminary and subject to change as updates are received.

Figure 9: Percent of notifications of laboratory-confirmed influenza, Australia, 1 January to 14 May 2023, by subtype and state or territory*

Source: NNDSS

*NNDSS notification data provided for the current and most recent weeks may be incomplete. All data are preliminary and subject to change as updates are received.
### Table 2: Australian influenza viruses typed by haemagglutination inhibition (HI) assay from the WHOCC, 1 January to 14 May 2023*

<table>
<thead>
<tr>
<th>Strain</th>
<th>ACT</th>
<th>NSW</th>
<th>NT</th>
<th>QLD</th>
<th>SA</th>
<th>TAS</th>
<th>VIC</th>
<th>WA</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>A(H1N1) pdm09</td>
<td>32</td>
<td>46</td>
<td>24</td>
<td>8</td>
<td>35</td>
<td>23</td>
<td>197</td>
<td>1</td>
<td>366</td>
</tr>
<tr>
<td>A(H3N2)</td>
<td>9</td>
<td>29</td>
<td>4</td>
<td>2</td>
<td>24</td>
<td>4</td>
<td>51</td>
<td>1</td>
<td>124</td>
</tr>
<tr>
<td>B/Victoria lineage</td>
<td>2</td>
<td>15</td>
<td>205</td>
<td>2</td>
<td>10</td>
<td>1</td>
<td>66</td>
<td>27</td>
<td>328</td>
</tr>
<tr>
<td>B/Yamagata lineage</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>43</td>
<td>90</td>
<td>233</td>
<td>12</td>
<td>69</td>
<td>28</td>
<td>314</td>
<td>29</td>
<td>818</td>
</tr>
</tbody>
</table>

*Viruses tested by the WHOCC are not necessarily a random sample of all those in the community. State indicates the residential location for the individual tested, not the submitting laboratory. There may be up to a month delay on reporting of samples.

#### 2.6. Vaccine match and effectiveness

**WHOCC**
- In the year to date, of the 818 samples referred to the WHOCC, 95.9% of influenza A(H1N1) isolates, 75.0% of influenza A(H3N2) isolates, and 99.4% of influenza B/Victoria isolates characterised were antigenically similar to the corresponding vaccine components.

**Australian Influenza Vaccines Composition 2023**
- All 2023 southern hemisphere [seasonal influenza vaccinations](#) registered for use in Australia are quadrivalent influenza vaccines (QIVs).
- The influenza virus strains included in egg-based QIVs in Australia in 2023 are:
  - A/Sydney/5/2021 (H1N1) pdm09-like virus;
  - A/Darwin/9/2021 (H3N2)-like virus;
  - B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
  - B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
- The influenza virus strains included in cell-based QIVs in Australia in 2023 are:
  - A/Sydney/5/2021 (H1N1) pdm09-like virus;
  - A/Darwin/6/2021 (H3N2)-like virus;
  - B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
  - B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

**Vaccine effectiveness**
The best way to determine how well the vaccine protects against circulating viruses during the season is by determining the vaccine effectiveness. Vaccine effectiveness is usually estimated from observational studies and is calculated after the end of the influenza season, though interim analyses are sometimes available where there is sufficient data.

It is too early to assess vaccine match and effectiveness for this season.